Skip to Content

Selexipag Disease Interactions

There are 2 disease interactions with selexipag:


Selexipag (Includes selexipag) ↔ liver impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Liver impairment can increase exposure to selexipag and its metabolites. No dose adjustment is necessary in patients with mild impairment, but a once a day regimen is recommended in patients with moderate hepatic impairment. There is no experience with selexipag in patients with severe hepatic impairment and its use should be avoided in these patients.


Selexipag (Includes selexipag) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No adjustment to the dosing regimen of selexipag is required in patients with estimated glomerular filtration rate > 15 mL/min/1.73m2. There is no clinical experience with selexipag in patients with glomerular filtration rates lower than this, or in patients undergoing dialysis.

Selexipag drug interactions

There are 512 drug interactions with selexipag

Selexipag alcohol/food interactions

There is 1 alcohol/food interaction with selexipag

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.